

theclinics.com

[Clinics Home](#)
[About Clinics](#)
[Hot Topics](#)
[Special Offers](#)
[CME](#)

Register or Login: Password: **SIGN IN** Auto-Login [\[Reminder\]](#)

Search for **GO**

[Advanced Search - MEDLINE](#) - [My Recent Searches](#) - [My Saved Searches](#) - [Search Tips](#)

CLINIC HOME
CURRENT ISSUE
PREVIOUS ISSUES
SEARCH THIS CLINIC
SUBSCRIBE OR RENEW
BUY BACK ISSUES
ACTIVATE ONLINE ACCESS
FORTHCOMING ISSUES
E-MAIL ALERTS
CLINIC INFORMATION
<ul style="list-style-type: none"> • Author Information • Abstracting/Indexing • Contact Information • Media Information • Permissions • Pricing Information
RELATED SITES
CAREER OPPORTUNITIES
MY PDA

Volume 25, Issue 4, Pages 1089-1109
(November 2007)

◀ **previous** 12 of 19 **next** ▶

Anaplastic Oligodendroglioma and Oligoastrocytoma

Martin J. van den Bent, MD 

Until approximately 15 years ago, the diagnosis of an oligodendroglioma (OD) was merely as a pathologic entity. The only clinical relevant meaning of this histologic diagnosis was the observation that the prognosis of OD was in general better than that of astrocytic tumors of similar grade. This changed with the recognition of the marked sensitivity to PCV chemotherapy of these tumors, although the best timing of chemotherapy still is unclear. Observations have led to the current tendency to consider 1p/19q loss low-grade and anaplastic oligodendroglioma a separate biologic entity, at least within clinical trials, since they have a much better outcome.

Neuro-Oncology Unit, Daniel den Hoed Cancer Clinic/Erasmus University Medical Center, PO Box 5201, 3008AE Rotterdam, the Netherlands

PII: S0733-8619(07)00087-4

doi:10.1016/j.ncl.2007.07.013

© 2007 Elsevier Inc. All rights reserved.

▶ ABSTRACT
FULL TEXT
FULL-TEXT PDF (1062 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE

More periodicals:

[FIND A PERIODICAL](#)

[FIND A PORTAL](#)

[GO TO PRODUCT CATALOG](#)

Copyright © 2007 Elsevier, Inc. All rights reserved | [Privacy Policy](#) | [Terms & Conditions](#) | [Feedback](#) | [About Us](#) | [Help](#) | [Contact Us](#) |
The content on this site is intended for health professionals.